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Abstract 
Despite their controversial physiology, sigma-1 (1) receptors are intriguing targets for the 
development of therapeutic agents for central nervous system diseases. With the aim of providing 
versatile pharmacological tools to study 1 receptors, we developed three 1 fluorescent tracers by 
functionalizing three well characterized 1 ligands with a fluorescent tag. A good compromise 
between 1 binding affinity and fluorescent properties was reached, and the 1 specific targeting of 
the novel tracers was demonstrated by different techniques: photolabeling, confocal microscopy and 
flow cytometry. These novel ligands were also successfully used in competition binding studies by 
flow cytometry, showing their utility in nonradioactive binding assays as an alternative strategy to 
the more classical radioligand binding assays. To the best of our knowledge these novel tracers are 
the first 1 fluorescent ligands to be developed, and represent promising tools to strengthen 1 
receptors related studies. 
 
1. Introduction  
The existence of sigma (σ) receptors was first reported in 1976 when they were considered as 
subtypes of opiate receptors [1]. Later studies clarified that they are a unique set of proteins 
divided into two subtypes, namely 1 and 2. The 2 subtype is the lesser known: it has not yet 
been cloned, and different hypotheses about its identity have been formulated [3‒4]. Despite this 
paucity of information, interest in 2 receptor research is on the increase because this subtype is 
overexpressed in several cancers and its activation through ligands leads cancers cells to death 
[5‒8]. Worthy of note is also the efficacy of 2 ligands in resistant tumors that shed light on novel 
strategies for tumor treatments [9]. On the other hand, 1 receptor was cloned right after the two 
subtypes were discovered [10, 11]. Several structures were proposed for this 223 amino-acids 
protein and the most accepted model represents the 1 receptor made of three hydrophobic regions 
two of which are trans-membrane spanning segments. The NH2 and the COOH termini of the 1 
protein are on the same side of the cell compartment where a possible endogenous ligand, not yet 
identified, regulates its function [12]. Progesterone, sphingolipid-derived amines (D-erythro-
sphingosine) and more recently N,N-dimethyltryptamines have been proposed as 1 endogenous 
ligands [13‒15]. Because of the important therapeutic potentials (e.g. treatment of anxiety, 
depression, schizophrenia, etc) linked to1 receptor targeting, interest in 1 receptor research is 
on the increase [16]. Recent evidence has shown that1 receptor can naturally form dimers and/or 
oligomer and that heteromers between 1 and D2 receptor play an important role in cocaine 
addiction [17, 18]. These dimers/oligomers may lead to different functional forms of the 1 
receptor (such as agonist or antagonist activity). All these lines of evidence make novel 
pharmacological tools appealing for the study of the still controversial1 receptor physiology. 
With this aim, we produced three 1 receptor fluorescent tracers starting from previously well 
characterized 1 receptor ligands. We adopted the same strategy that was shown to be successful 
for 2 fluorescent ligands: the appropriate 1 pharmacophore was linked through a spacer to a 
green emitting fluorescent tag [19‒21]. In particular, as 1 pharmacophores we selected 4-methyl-
1-[4-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)butyl]piperidine PB190 and 4-methyl-1-[4-
(6-methoxy-naphthalen-1-yl)butyl]piperidine PB212 (Figure 1) which were shown to be 
respectively a 1 selective agonist and a 1 selective antagonist by both in vitro and in vivo assays 
[22‒26]. We also selected 4-cyclohexyl-1-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-
yl)propionyl]piperazine (Figure 1, 1) which showed excellent 1 affinity and 1 vs 2 selectivity 
[27]. The methoxy group present in these 1 ligands was replaced by a hexamethylenoxy chain 
carrying in the  position a 4-N,N-dimethylphthalimide moiety. These choices were made on the 
basis of data obtained from 2 receptor fluorescent ligands: the position on the naphthalene or 
tetralin ring and the nature of the linker showed to be well tolerated with 4-N,N-
dimethylphthalimide conferring optimal fluorescent properties that allowed successful 
experiments in living cells by flow cytometry and confocal microscopy.  
2. Results and Discussion 
2.1. Chemistry 
The synthetic pathway for final compounds 5, 6 and 9, is depicted in Scheme 1. The already known 
piperidines PB190 and PB212 [22] and the piperazine 1 [27] were demethylated by reaction with 
BBr3 to provide the corresponding phenolic intermediates 2, 3 and 8, although phenol 3 was 
previously obtained through another synthetic pathway [28]. Alkylation of the phenolic intermediates 
2, 3 and 8 with the already known mesyl derivative 4 [20] provided final fluorescent compounds 5, 6 
and 9. Final comompounds 6 and 9 were converted into the corresponding hydrochloride salts with 
gaseous HCl, whereas 5 was converted into the corresponding oxalate salt. 
2.2.  Receptors Radioligand binding  
Results from binding assays are expressed as inhibition constants (Ki values) in Table 1. As in the σ2 
receptors fluorescent ligands, the introduction of the fluorescent tag connected through the 
hexamethylenoxy linker at the 2- or 5-position of the naphthalene and tetralin ring respectively, 
produced a decrease in the σ1 receptor affinity with respect to the corresponding lead compounds. 
Only compound 5 presented affinity values at both  receptors (Ki = 3.61 nM at the 1, and Ki = 48.3 
nM at the 2) comparable to those of lead compound PB190 (Ki = 1.01 nM at the 1, and Ki = 48.7 
nM at the 2). Final compounds 6 and 9 presented a 100-fold drop in the 1 affinity (Ki = 5.20 nM 
and Ki = 13.1 nM, respectively) in comparison to the lead compounds PB212 and 1, respectively (Ki 
= 0.03 nM and Ki = 0.11 nM, respectively). By contrast, the affinity at the 2 receptors only slightly 
decreased for 6 (2.5-fold) in comparison to its lead compound PB212, whereas 2 receptor affinity of 
9 was 5-fold higher than 2 receptor affinity displayed by 1. Despite the decrease in the 1 affinity 
compared to the lead compounds, the three fluorescent ligands still demonstrated strong nanomolar 
σ1 binding, and compounds 5 and 6 also kept a certain 1 versus 2 receptor selectivity (10-fold), 
which was lower (3-fold) in 9. Taking these data together, the strategy adopted to obtain 2 receptor 
fluorescent ligands showed to be successful also for 1 receptor fluorescent ligands. 
2.3. Photolabeling and Cell Viability Assay. To demonstrate the universality of specific binding of 
the novel tracers to 1 receptors we performed a photolabeling assay, selecting compounds 6 and 9 
bearing structurally different basic moieties and using rat adrenal gland phaeochromocytoma PC12 
cell membranes as a convenient source of 1 receptors. As shown in Figure 2.A, both 6 and 9 
effectively protected against photolabeling of 1 receptor by [125I]-Iodoazidophenpropimorph. 
Further, as shown in Figure 2. B, the cytoprotective properties of compound 9 were assessed in a 
MTT cell viability assay upon toxicity mediated by paraquat. It is clear that compound 9 protects 
against such toxicity and therefore may be useful for oxidative stress treatments. 
2.4. Fluorescent Ligands Studies.  
2.4.1. Fluorescent Properties. The fluorescent properties are listed in Table 1. The three compounds 
displayed very similar maximum excitation wavelength (λex = 390 nm) and maximum emission 
wavelength (λem ~ 520 nm), with an important difference between λex and λem (i.e., Stokes shift) in 
accordance to the spectra recorded for the 2 ligands with the same fluorescent tag [20, 21]. 
Measurement of quantum yields (QY) demonstrated the environment sensitive properties (low 
fluorescence intensity in polar solvent such as EtOH, but high fluorescence in nonpolar solvents such 
as CHCl3), proper for the 4-N,N-dimethylphthalimide fluorescent tag, as recorded for 2 ligands.  
2.4.2. Imaging of ARPE19 cells with compound 9 by confocal microscopy.  
In Figure 3 the labeling of human retinal pigment epithelia ARPE19 cells with compound 9 shows 
fluorescent signals in intracellular membranes. The fluorescent signals were protected by PB190, 
indicating the specificity of binding to  receptors.  
2.4.3 Detection of  receptors by flow cytometry. Cellular up-take of compounds 5 and 6 was studied 
by flow cytometry in two human breast tumor MCF7 cell lines: MCF7wt and MCF71. Both these 
cell lines were thoroughly and previously characterized: the former overexpresses 2 receptors (Bmax 
= 2.02 pmol/mg protein) [4, 20] whereas 1 receptors’ expression is very low (Bmax = 0.17 pmol/mg 
protein) [4, 29]; the latter is obtained by stable transfection of MCF7 cells with 1 c-DNA to obtain 
a good expression of 1 receptors (Bmax = 3.45 pmol/mg protein) [21, 29]. All of the experiments were 
performed by incubation of the two cell lines for 45 and 75 min with either compound 5 or 6 at 100 
nM, as the fluorescence signal increased in a dose-dependent manner, reaching a plateau at 100 nM. 
Despite their 10-fold 1 vs 2 selectivity, compounds 5 and 6 still display 2 receptor affinity (Ki = 
48.3 nM for 5 and Ki = 45.6 nM for 6). Therefore, the 2 selective ligand 2-(3-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl)propyl)-5-methoxy-3,4-dihydroisoquinolin-1(2H)-one 10 [30] (Ki = 
2435 nM at the 1, and Ki = 4.24 nM at the 2) was used at 10 M to mask the possible fluorescent 
signal generated by the 2 targeting of the fluorescent compounds. The 1 specificity of the 
fluorescent tracers (100 nM) was demonstrated by comparison of the fluorescent signals by MCF71 
and MCF7wt, (Figure 4) upon treatment with (+)-pentazocine and 10. In MCF7wt cells, where the 
fluorescence intensity was very low in each experimental condition, no change in the fluorescent 
signal by either 5 or 6 was detected upon administration of (+)-pentazocine or 10 (Figure 4, right 
panels). In MCF71 cells the administration of (+)-pentazocine (10 M) strongly decreased the 
fluorescent signal by both 5 and 6 (with the signal by 5 completely abated) whereas, treatment with 
compound 10 (10 M) only slightly decreased fluorescence by both the tracers. As, expected, co-
administration of both (+)-pentazocine and 10 completely abated the fluorescent signals by both the 
tracers (Figure 4, left panels). These results reflected the expression of  receptors in the MCF7 cell 
lines and suggested that these tracers, administered at 100 nM, bind 1 receptors rather specifically, 
with a negligible interference by 2 receptors. In MCF71, either 5 (100 nM) or 6 (100 nM) were 
dose dependently displaced (as demonstrated by the progressive decrease of fluorescence) by pre-
incubation with increasing concentrations of either PB190 or PB212 (Figures 5 and 6, A and B; left 
panels; basal fluorescence of MCF7 cells in the presence of PB190 or PB212 reported in Figure 1 in 
the supporting information), which were used as 1 reference non-fluorescent compounds (from 1 
nM to 10 M). The same experiment was performed with (+)-pentazocine and a dose-dependent 
displacement was again recorded, with more linear results obtained by 45 min incubation time (Figure 
7). By contrast, no differences were shown between the two incubation times studied (45 min or 75 
min) when 5 or 6 were displaced by PB190 and PB212. As expected from a cell line with very low 
amount of 1 receptors, the displacement was far more modest in MCFwt (Figures 5‒7, A and B; 
right panels). The fluorescence intensity results obtained by either 5 or 6 in MCF71 cells by dose-
dependent displacement of the 1 receptor ligands studied, served to generate binding curves for 
PB190, PB212 and (+)-pentazocine allowing the measurement of the IC50 values of these compounds 
for the human 1 receptors in MCF7 cells (Table 2). Differences between radioligand binding assays 
performed on animal tissues and human cells homogenates have already been reported for  
receptors, with slightly lower binding affinities from the latter experiment [31]. The IC50 values 
obtained by flow cytometry on MCF7 cells were in accordance with such trend, demonstrating the 
utility of 1 receptors fluorescent ligand as tools to detect their presence in living cells and to 
conveniently perform 1 binding assays of novel ligands in spite of the radioligand binding assays. 
4. Conclusions 
Three 1 fluorescent tracers were synthesized by functionalization of three well characterized 1 
ligands with a fluorescent tag. A good compromise between binding affinity at the 1 subtype and 
fluorescent properties was obtained, with all the compounds displaying low nanomolar 1 receptor 
affinity. Their  receptor specificity was demonstrated by protection with -specific compounds in 
different cell lines through different techniques: photolabeling (compounds 6 and 9), confocal 
microscopy (compound 9) and flow cytometry (compounds 5 and 6). We also demonstrated that 
through the use of these fluorescent tracers in flow cytometry, 1 binding assays of novel ligands can 
be conveniently performed in spite of the more classical radioligand binding assays that involves the 
use of radioligands such as [3H]-(+)-pentazocine. To the best of our knowledge, these compounds are 
the first 1 fluorescent ligands to be produced and successfully employed, and they emerge as useful 
tools to empower 1 receptors studies. 
5. Experimental section 
5.1. Chemistry Both column chromatography and flash column chromatography were performed 
with 60 Å pore size silica gel as the stationary 300 phase (1:30 w/w, 63–200 m particle size, from 
ICN and 1:15 w/w, 15–40 m particle size, from Merck, respectively). Melting points were 
determined in open capillaries on a Gallenkamp electrothermal apparatus. Purity of tested compounds 
was established by combustion analysis, confirming a purity >95%. Elemental analyses (C, H, N) 
were performed on an Eurovector Euro EA 3000 analyzer; the analytical results were within ±0.4% 
of the theoretical values, unless otherwise indicated. 1H NMR spectra were recorded on a Mercury 
Varian 300 MHz using CDCl3 as solvent, unless otherwise reported. The following data were 
reported: chemical shift () in ppm, multiplicity (s, singlet; d, doublet; t, triplet; q, quadruplet; m, 
multiplet), integration and coupling constants in hertz. Recording of mass spectra was done on an 
Agilent 6890-5973 MSD gas chromatograph/mass spectrometer and on an Agilent 1100 series LC–
MSD trap system VL mass spectrometer; only significant m/z peaks, with their percentage are 
reported in parentheses. Chemicals were from Aldrich, TCI and Alfa Aesar and were used without 
any further purification. 
5.2. General procedure for the synthesis of phenolic intermediates (2, 3, 8) 
A solution of one among the methoxy derivatives PB190, PB212 and 1 (1.0 mmol) in anhydrous 
CH2Cl2 (10 mL) and under Argon was cooled to ‒78 °C and then added in a dropwise manner with 
BBr3 (3.0 mmol, 0.3 mL). The mixture was stirred overnight under Argon while it slowly reached 
room temperature. After cooling in an ice bath, H2O was added to the mixture which was basified 
with Na2CO3. The resulting mixture was extracted with CH2Cl2 (3 × 10 mL) and the organic phases 
collected, dried (Na2SO4) and concentrated under reduced pressure to afford crude oils which 
provided the title compounds upon purification through column chromatography (CH2Cl2/MeOH, 
95:5).  
5.2.1. 5-[4-(4-methylpiperidine-1-yl)butyl]-5,6,7,8-tetrahydronaphthalen-2-ol (2): was obtained 
in 69% yield (0.204 g) as beige solid: mp = 184-186 °C; GS-MS m/z: 301 (M+, 20), 112 (100); LC-
MS (ESI-) m/z: 300 [M ‒ H]‒. 
5.2.2. 5-[4-(4-methylpiperidine-1-yl)butyl]naphthalen-2-ol  (3): was obtained in 69% yield (0.202 
g) as beige solid: mp = 182-184 °C (literature[28] mp = 183-185 °C); GS-MS m/z: 297 (M+, 20), 112 
(100); LC-MS (ESI-) m/z: 296 [M ‒ H]‒; LC-MS-MS 296: 156. 
5.2.3. 4-Cyclohexyl-1-[3-(5-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)propionyl]piperazine 
(8): was obtained in 90% yield (0.33 g) as sticky solid. 1H-NMR δ 1.05-1.35 [m, 6H, cyclohexyl), 
1.55-2.05 (m, 10H, COCH2CH2CHCH2CH2 and cyclohexyl CH2), 2.20 – 2.45 (m, 3H, benzyl CH 
and CH2), 2.50-2.58 (m, 4H, CH2 piperazine), 2.60-2.75 (m, 2H, CH2CO), 2.80-2.85 (m, 1H, CHN), 
4.38-4.70 [m, 4H, CON(CH2)2], 5.20 (broad s, 1H, OH), 6.60 (d, J = 7.15 Hz, 1H aromatic), 6.78 (d, 
J = 7.7 Hz, 1H, aromatic), 7.00 (t, J = 7.8 Hz, 1H, aromatic); GS-MS m/z: 370 (M+, 30), 138 (70), 
125 (100), 112 (80). 
5.3. General procedure for the synthesis of final fluorescent compounds (5, 6 and 9). 
A solution in DMF (10 mL) of one among the phenol intermediates 2 or 3 or 8 (1.0 mmol) was added 
with the mesyl derivative 4 (1.0 mmol, 0.37 g) and K2CO3 (1.2 mmol, 0.16 g) to provide a mixture 
which was stirred at 150 °C overnight. After concentration under reduced pressure the crude residue 
which was taken up with water was extracted with  CH2Cl2 (3 × 10 mL) and the organic phases 
collected were dried (Na2SO4) and evaporated under reduced pressure to provide a crude oil which 
was purified by column chromatography (CH2Cl2/MeOH, 95:5) to afford the title compounds. 
5.3.1. 5-(dimethylamino)-2-(6-((5-(4-(4-methylpiperidin-1-yl)butyl)-5,6,7,8-
tetrahydronaphthalen-2-yl)oxy)hexyl)isoindoline-1,3-dione. (5) The title compound was obtained 
in a 50% yield (0.286 g) as a bright yellow oil. 1H-NMR δ 0.98 (d, J = 5.7 Hz, 3H, CHCH3), 1.25-
2.00 [m, 19H, N(CH2)2, CH2(CH2)4 , CH(CH2)3 e NH], 2.25-2.40 (m, 3H, benzyl CH and CH2), 2.60-
2.70 (m, 4H, N(CHH)2 and CH2CH2CH2N), 2.85-2.95 (m, 2H, N(CHH)2), 3.10 [s, 6H, N(CH3)2], 
3.62 (t, J = 7.15 Hz, 2H, (CO)2NCH2), 3.88 (t, J = 6.6 Hz, 2H, OCH2), 6.50-7.65 (m, 6H, aromatic); 
LC-MS (ESI+) m/z: 574 [M + H]+; LC-MS-MS 574: 203. Anal. (C36H51N3O3·C2O4H2·½H2O) C, H, 
N.  
5.3.2. 5-(dimethylamino)-2-{6-[(5-(4-(4-methylpiperidin-1-yl)butyl)naphthalen-2-
yl)oxy]hexyl}isoindole-1,3-dione (6). The title compound was obtained in a 50% yield (0.284 g) as 
a bright yellow oil. 1H-NMR δ 0.95-1.00 (m, 3H, NHCH3), 1.15-2.05 [m, 17H, CH(CH2)2, 
(CO)2NCH2(CH2)4CH2 and ArCH2(CH2)2], 2.60-2.75 [m, 2H, N(CHH)2], 2.85-2.95 [m, 2H, 
N(CHH)2], 2.98-3.05 [m, 4H, Ar(CH2)3CH2N], 3.10 [s, 6H, N(CH3)2], 3.65 (t, J = 7.15 Hz, 2H, 
(CO)2NCH2), 4.05 (t, J = 6.6 Hz, 2H, OCH2), 6.70-8.05 (m, 9H, aromatic); LC-MS (ESI
+) m/z: 570 
[M + H]+; LC-MS-MS 570: 203.  Anal. (C36H47N3O3·HCl·1.75H2O) C, H, N. 
5.3.3. 2-(6-((5-(3-(4-cyclohexylpiperazin-1-yl)-3-oxopropyl)-5,6,7,8-tetrahydronaphthalen-1-
yl)oxy)hexyl)-5-(dimethylamino)isoindole-1,3-dione (8). The title compound was obtained in a 
57% yield as a yellow oil (0.366 g). 1H-NMR δ 1.05-2.05 [m, 24H, piperazine CH2, OCH2(CH2)4, 
CH(CH2)3],  2.20-2.85 [m, 10H, CHN(CH2 )2, CH2CO, benzyl CH and CH2],  3.11 [s, 6H, (NCH3)2], 
3.38-3.42 [m, 2H,  CON(CHH)2], 3.58-3.45 [m, 4H, (CO)2NCH2 and CON(CHH)2], 3.90 (t, 2H, J = 
6.1 Hz, OCH2),  6.60-6.65 (m, 6H, aromatic); LC-MS (ESI
+) m/z: 665 [M + Na]+; LC-MS-MS 665: 
497, 393.  Anal. (C39H54N4O4·2HCl) C, H, N. 
5.4. Biology  
5.4.1. Materials. [3H]-DTG (50 Ci/mmol), and (+)-[3H]-pentazocine (30 Ci/mmol) were purchased 
from PerkinElmer Life and Analytical Sciences (Boston, MA). DTG was purchased from Tocris 
Cookson Ltd., U.K. (+)-Pentazocine was obtained from Sigma−Aldrich (Milan, Italy). Male Dunkin 
guinea pigs and Wistar Hannover rats (250−300 g) were from Harlan, Italy. Cell culture reagents 
were purchased from EuroClone (Milan, Italy). 
5.4.2. Competition Binding Assays. All the procedures for the binding assays were previously 
described. 1 And 2 receptor binding were carried out according to Berardi et al. [27]. [3H]-DTG, 
1,3-di-2-tolylguanidine (30 Ci/mmol) and (+)-[3H]-pentazocine (34 Ci/mmol) were purchased from 
PerkinElmer Life Sciences (Zavantem, Belgium). DTG was purchased from Tocris Cookson Ltd. 
(UK). (+)-Pentazocine was obtained from Sigma–Aldrich-RBI s.r.l. (Milan, Italy). Male Dunkin 
guinea pigs and Wistar Hannover rats (250–300 g) were from Harlan (Italy). The specific radioligands 
and tissue sources were, respectively: (a) 1 receptor, (+)-[3H]-pentazocine, guinea pig brain 
membranes without cerebellum; (b) 2 receptor, [3H]-DTG in the presence of 1 m (+)-pentazocine 
to mask 1 receptors, rat liver membranes. The following compounds were used to define the specific 
binding reported in parentheses: (a) (+)-pentazocine (73–87 %), (b) DTG (85–96 %). Concentrations 
required to inhibit 50% of radioligand specific binding (IC50) were determined using six to nine 
different concentrations of the drug studied in two or three experiments with samples in duplicate. 
Scatchard parameters (Kd and Bmax) and apparent inhibition constants (Ki values) were determined 
by nonlinear curve fitting, using Prism GraphPad software (version 3.0) [32]. 
5.4.3. Cell Culture. Human breast adenocarcinoma cell line (MCF7) was purchased from ICLC 
(Genoa, Italy), and were stably transfected with 1-receptor c-DNA (MCF71) as already described. 
Cells were grown in DMEM high-glucose medium supplemented with fetal bovine serum (10 %), 
and penicillin-streptomycin (1%) in a humidified incubator at 37 °C with a CO2 atmosphere. Human 
retinal pigment epithelia ARPE19 cells were purchased from ATCC and grown in complete growth 
medium (DMEM supplemented with fetal bovine serum 10%) and penicillin-streptomycin (1%) in 
cell culture incubator with 5% CO2. Mouse Motor Neuron NSC34 cells were purchased from 
Cedarlane company, Canada and were grown in 15 cm cell culture dishes in 50%/50% DMEM/F12 
supplemented with 10% fetal bovine serum and 1× penicillin-streptomycin (final 100 g/ml). Rat 
adrenal gland phaeochromocytoma PC12 cells were purchased from ATCC and were grown in RPMI 
1640 (Mediatech) supplemented with 10% heat-inactivated Horse serum (Corning), 5% fetal bovine 
serum, and penicillin-streptomycin (1%). 
5.4.4. ARPE19 Cell labeling and imaging. Drug treatment and imaging of ARPE cells was done in 
HBSS. For control, some wells were pretreated with 100 M PB190 for 40 min. Cells were further 
treated with compound 9 0.5 M for 40 min, then rinsed twice in HBSS and imaged under A1 
confocal microscope with excitation wavelength of 408 nM and emission detection of 525 nM.  
5.4.5. MTT cell viability assay.  
ARPE 19 cells were seeded to 96 well plates to a density of 30000 cells/well and grown in complete 
growth medium to reach 100% confluency. Then 1 mM toxin Paraquat was applied with or without 
various concentrations of compound 9 and cells were incubated tor 24 h in complete growth media. 
Then wells were quickly aspirated and Thiazolyl Blue Tetrazolium Bromide (MTT, Sigma-Aldrich 
M2128) was applied under the dim light at concentration 0.5 mg/ml in phenol red free DMEM (100 
l/well) supplemented with fetal bovine serum 0.5%. After 3 hours of incubation 100 l of 10% 
Sodium Dodecyl Sulfate (SDS) was added per each well. Plates were left overnight in cell culture 
incubator to dissolve precipitate. Absorbance at  = 540 nM was detected in 96 well plate reader. 
5.4.6. Photolabeling experiment. NSC34 cells and PC12 cells were grown on 15 cm cell culture dishes in 
complete growth medium. Cells were rinsed with DPBS and detached with cell culture scraper and collected 
into 15 ml falcon tubes, span 1000 rpm for 3 min. Pellet was gently rinsed with PBS, cells resuspended,  
sonicated and span at 5000G. Soluble fraction was collected and span at 100000G. Soluble fraction was 
discarded and translucent pellet was resuspended by sonication on ice. The protein concentration was 
measured by the Bradford Bio-Rad assay. For photolabeling, each sample contained 100 l of 5 g/l 
protein. Where applicable, (+)-pentazocine, DTG were preincubated with the homogenate for 30 min 
at room temperature. Then carrier-free [125I]-IAF [33] (approximately 1 nM) was added for 30 min, 
and the membrane preparations were further incubated in the dark at room temperature. After 
incubation, the samples were illuminated with an AH-6 mercury lamp for 7.5 s, and Laemmli buffer 
was added to each sample. Samples were separated by SDS PAGE, the gel was stained and dried, and 
exposed to a phosphor screen (Molecular Dynamics) for 24 h. The cassette was scanned on a Storm 
Phosphoimager (Molecular Dynamics) to produce the resulting autoradiogram. 
5.4.7. Flow cytometry studies. MCF7 and MCF71 cells were incubated with increasing 
concentrations (0.1, 1, 10, and 100 nmol/L and 1 and 10 μmol/L) of either PB190 or PB212 followed 
by 100 nmol/L of either compounds 5 or 6 for 45 or 75 min at 37 °C. To mask 2 receptors, compound 
10 (10 μmol/L) was co-incubated. When indicated, cells were treated with increasing concentrations 
(1, 10, and 100 nmol/L and 1 and 10 μmol/L) of (+)-pentazocine or PB190 or PB212, followed by 
100 nmol/L of compounds 5 or 6 for 45 or 75 min at 37 °C. At the end of the incubation periods, cells 
were washed twice with PBS, detached with 200 µl of Cell Dissociation Solution (Sigma Chemical 
Co.) for 10 min at 37°C, centrifuged at 13,000 × g for 5 min and re-suspended in 500 µL of PBS. The 
fluorescence was recorded using a Bio-Guava® easyCyte™ 5 Flow Cytometry System (Millipore, 
Billerica, MA), with a 530 nm band pass filter. For each analysis, 50,000 events were collected and 
analysed with the InCyte software (Millipore). 
5.5. Fluorescence Spectroscopy. Emission and excitation spectra of compounds 5, 6 and 9, were 
determined in CHCl3 and in PBS buffer solution as previously reported. Fluorescence quantum yields 
were calculated with respect to quinine sulfate as previously reported [19]. 
Abbreviations: DTG, di-2-tolylguanidine; DMEM, Dulbecco's modified Eagle's medium; PBS, 
phosphate buffered saline; SDS, Sodium Dodecyl Sulfate. 
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Table 1.  Receptor Affinities of Final and Lead-Compounds and Fluorescence Properties. 
 
 
[a] Values are the means of n ≥ 3 separate experiments, in duplicate. [b] Fluorescence properties of 
compounds were evaluated on compound as free base in EtOH solutions. [c] QY were evaluated as 
in 20; [d] Data from ref 22; [e] Data from ref 27.  
  
 Ki nM ± SEM (nM)[a]     
compound 1 2 ex nm[b] em nm[b] 
QY 
EtOH[c] 
QY 
CHCl3[c] 
PB190[d] 1.01 ± 0.41 48.7 ± 9.2     
PB212[d] 0.03 ± 0.013 17.9 ± 5.3     
1[e] 0.11 ± 0.01 179 ± 56     
5 3.61 ± 0.4 48.3 ± 6.0 390 510 0.02 0.5 
6 5.20 ± 0.17 45.6 ± 4.6 390 520 0.02 0.4 
9 13.1 ± 5.02 38.4 ± 10.9 390 520 0.02 0.4 
DTG  35.4±5.8     
(+)-pentazocine 4.52±0.7      
Table 2.  Receptor Affinities of Reference  Receptor ligands by flow-cytometry with novel 1 
fluorescent ligands. 
 1; IC50 nM ± SEM[a] 
compound 5[b] 6[b] 
PB190[c] 11.3 ± 2.4 12.1 ± 1.4 
PB212[c] 15.5 ± 2.3 10.6 ± 1.2 
(+)-pentazocine[d] 8.24 ± 1.2 7.59 ± 0.8 
 
[a] Values are the means of n ≥ 2 separate experiments, in duplicate. [b] IC50 values from binding 
curves obtained by dose dependent displacement of 5 (100 nM) or 6 (100 nM) by 1 reference 
compounds (PB190, PB212 and (+)-pentazocine) in MCF71 cells by flow cytometry. [c] Data from 
75 min incubation time. [d] Data from 45 min incubation time. The experiments were performed in 
the presence of the 2 masking agent 10 (10 M). 
 
  
Figure 1. 
 
  
  
 Figure 2. Compounds 6 and 9 protected  receptor photolabeling by [125I]-
Iodoazidophenpropimorph and also protected against paraquat-mediated toxicity. A. Photolabeling 
by [125I]-Iodoazidophenpropimorph in PC12 cell membranes. 5 M (+)-Pentazocine [(+)-Pent] and 
di-2-tolylguanidine (DTG) specifically protected the  receptor band. PC12 cells were used as a 
convenient sourse of  receptor to show that both compounds 6 and 9 protected  receptor 
photolabeling. B. Compound 9 in concentration-dependent manner protects against paraquat-
mediated toxicity as estimated by a MTT assay in ARPE19 cells. All drugs were applied 
simultaneously for 24 hours. 
  
  
 
 
 
Figure 3. Labeling of ARPE19 Cells with compound 9. Signal is localized to intracellular 
membranes. Lower intensity of labeling is detected when cells were prelabeled with PB190 100 M.   
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Figure 4. Flow Cytometry analysis (cell associated fluorescence vs cell count) of MCF71 and 
MCF7wt, exposed to compound 5 or 6 and treated with compound 10 (10 M) to mask 2 receptors, 
or (+)-pentazocine (10 M) to mask 1 receptors, or both 10 (10 M) with (+)-pentazocine (10 M).  
A) Displacement of 5 (100 nM, yellow curve): black curve: control; red curve: 10 M 10; green 
curve: 10 M (+)-pentazocine; violet curve: 10 M 10 with (+)-pentazocine 10 M. B) Displacement 
of 6 (100 nM, yellow curve): black curve: control; red curve: 10 M 10; green curve: 10 M (+)-
pentazocine; violet curve: 10 M 10 with (+)-pentazocine 10 M. 
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Figure 5. Flow Cytometry analysis (cell associated fluorescence vs cell count) of MCF71 and 
MCF7wt, exposed to 5 and treated with 10 (10 M) to mask 2 receptors.  A) Displacement of 5 (100 
nM, yellow curve) with increasing concentrations of PB190: black curve: control; orange curve: 1 
nM PB190; red curve: 10 nM PB190; green curve: 100 nM PB190; blue curve: 1 µM PB190; violet 
curve: 10 µM PB190. B) Displacement of 5 (100 nM, yellow curve) with increasing concentrations 
of  PB212: black curve: control; orange curve: 1 nM PB212; red curve: 10 nM PB212; green curve: 
100 nM PB212; blue curve: 1 µM PB212; violet curve: 10 µM PB212.  
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Figure 6. Flow Cytometry analysis (cell associated fluorescence vs cell count) of MCF71 and 
MCF7wt, exposed to 6 and treated with 10 (10 M) to mask 2 receptors.  A) Displacement of 6 (100  
nM, yellow curve) with increasing concentrations of PB190: black curve: control; orange curve: 1 
nM PB190; red curve: 10 nM PB190; green curve: 100 nM PB190; blue curve: 1 µM PB190; violet 
curve: 10 µM PB190. B) Displacement of 6 (100 nM, yellow curve) with increasing concentrations 
of PB212: black curve: control; orange curve: 1 nM PB212; red curve: 10 nM PB212; green curve: 
100 nM PB212; blue curve: 1 µM PB212; violet curve: 10 µM PB212.  
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Figure 7. Flow Cytometry analysis (cell associated fluorescence vs cell count) of MCF71 and 
MCF7wt, exposed to 5 or 6 and treated with 10 (10 M) to mask 2 receptors.  A) Displacement of 
5 (100 nM, yellow curve) with increasing concentrations of (+)-pentazocine: black curve: control; 
orange curve: 1 nM (+)-pentazocine; red curve: 10 nM (+)-pentazocine; green curve: 100 nM (+)-
pentazocine; blue curve: 1 µM (+)-pentazocine; violet curve: 10 µM (+)-pentazocine. B) 
Displacement of 6 (100 nM, yellow curve) with increasing concentrations of (+)-pentazocine: black 
curve: control; orange curve: 1 nM (+)-pentazocine; red curve: 10 nM (+)-pentazocine; green curve: 
100 nM (+)-pentazocine; blue curve: 1 µM (+)-pentazocine; violet curve: 10 µM (+)-pentazocine. 
  
MCF71 MCF7wt A) 
B) 
MCF71 MCF7wt 
Scheme 1. Reagents and Conditions: (a) BBr3, CH2Cl2, from ‒78 Cº to room temperature, overnight; 
(b) K2CO3, DMF, 150 Cº, overnight.   
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Table of Physical Properties and Elemental Analyses  
 
aElemental analyses were within ± 0.4% of the theoretical values for the formulas given. 
bRecrystallized from MeOH. cRecrystallized from MeOH/Et2O. 
 
 
  
  Calculated Found  
Comp. Formulaa C H N C H N mp, ºC 
5 C36H51N3O3·C2O4H2·½H2O 67.83 8.09 6.25 67.74 8.00 6.3 105–107b 
6 C36H47N3O3·HCl·1.75H2O 67.80 8.14 6.59 67.84 7.75 6.67 97–99b 
9 C39H54N4O4·2HCl 65.44 7.89 7.83 65.19 7.89 7.79 140–143b 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Compound 9 protected σ1 receptor against paraquat-mediated toxicity in concentration-
dependent manner protects as estimated by a MTT assay in ARPE19 cells. All drugs were applied 
simultaneously for 24 hours. 
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Figure 2. Basal fluorescence in MCF7σ1 or MCF7wt in the presence of PB190 or PB212 (10 µM, 
75 min), masking σ2 receptors with compound 10. 
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